New study from MD Anderson and BridgeBio’s Navire Pharma shows SHP2 inhibition overcomes multiple therapeutic-resistance mechanisms in lung cancer
New preclinical research from Â鶹ӳ» MD Anderson Cancer Center and BridgeBio Pharma, Inc. affiliate Navire Pharma, Inc., finds that the novel SHP2 inhibitor IACS-13909 is able to overcome multiple therapeutic-resistance mechanisms in non-small cell lung cancer (NSCLC), suggesting a possible new approach to treating cancers that have developed resistance to the targeted EGFR inhibitor osimertinib.
The data...
Combination immunotherapy benefits subset of patients with advanced prostate cancer
Results from a Phase II trial led by researchers at Â鶹ӳ» MD Anderson Cancer Center suggest that a combination of ipilimumab...